Abstract 32P
Background
Hypoxia is characterized by low oxygen levels in tissues and plays a significant role in the development and progression of gliomas. Hypoxia induces activation of several signals including STAT3 which has been implicated in the cancer progression and development of drug resistance including in gliomas used temozolomide (TMZ) via modulation of O6-methylguanin-DNA-methyltransferase (MGMT) mediated repair of TMZ-induced DNA damage.
Methods
Our study was focused on the expression of STAT3 and hypoxia related factors in a set of repeatedly resected glioma patients (one patient without treatment, seven patients with chemoradiotherapy) and glioma cell lines with normal and knockout STAT3 using IHC, mutational and RT-PCR analyses correlated with clinical data.
Results
In patients' samples, IHC analysis showed that in all but one repeated glioma resections from individual patients pSTAT3 levels were elevated. Higher pSTAT3 levels as well as MGMT methylation status corresponded with a shortened survival of these patients. Further analyses carried out in cryopreserved glioma samples revealed upregulation of STAT3 in an untreated patient corresponding with upregulation of hypoxia factors (HIF1α, HIF1β), proangiogenic factor VEGFA and EGFR. STAT3 knockout in glioma cells produced a similar trend - downregulation of hypoxia and proangiogenic factors.
Conclusions
Our results demonstrated a biological relationship between the expression of pSTAT3, hypoxia and proangiogenic factors and MGMT methylation in both cultivated glioma cells and glioma resected samples. Moreover, we discovered that pSTAT3 levels tend to increase in repeated resections. MGMT methylation status and increased pSTAT3 levels in these samples correlate with shorter survival of investiagted glioma bearing patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Ministry of Health, Czech Republic, project No. NU20-03-00360.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract